Impact of Upadacitinib on Laboratory Parameters and Related Adverse Events in Patients with RA: Integrated Data Up to 6.5 Years

By sjmartinez • January 6, 2024

Charles-Schoeman C, Giles JT, Lane NE, Choy E, Furst DE, Vencovský J, Wilson AG, Burmester GR, Coombs D, Penn SK, Khan N, Yee JB, Rahawi K, McInnes IB. Impact of Upadacitinib on Laboratory Parameters and Related Adverse Events in Patients with RA: Integrated Data Up to 6.5 Years. Rheumatol Ther. 2024 Jan 5. doi: 10.1007/s40744-023-00624-3. Epub ahead of print. PMID: 38180720.

Tags: JAK inhibitor, Laboratory parameters, Publications, Rheumatoid arthritis, Rheumatology, Upadacitinib

Comparing Changes in FDG-PET Activity in Sarcoidosis to Changes in Pulmonary Function Tests

Soo Hoo GW, Chang MR, Sather CC. Comparing Changes in FDG-PET Activity in Sarcoidosis to Changes in Pulmonary Function Tests. Arch Bronconeumol. 2024 Dec 5:S0300-2896(24)00452-6.[...]

CPX-351 plus gemtuzumab ozogamicin for relapsed/refractory acute myelogenous leukemia: a University of California Hematologic Malignancies Consortium trial

Oliai C, Park S, Damon LE, Jonas BA, Jeyakumar D, Wieduwilt MJ, Logan AC, Callas B, Hannigan CA, Gaut DL, Schiller GJ. CPX-351 plus gemtuzumab[...]

Decreases in hemoglobin and hematocrit may signal degree of hemorrhagic shock: retrospective evaluation in a dog model

Jahr JS, Dang J, Tong A, Iskandar S, Patel A, Grogan T, Hopster K, Driessen B, Gunther RA. Decreases in hemoglobin and hematocrit may signal[...]